



20752



BRAWN BIOTECH LTD.

26th May, 2025

The General Manager
The Department of Corporate Services,
BSE Limited, 25th Floor,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai -400001

BSE Scrip Code: 530207
Scrip ID: BRAWN

Sub: Outcome of the Board Meeting of the Company held on 26th May, 2025, and submissions of Audited Financial Results for quarter and financial year ended March 31st, 2025.

Ref: Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (SEBI Listing regulations).

Dear Sir/Ma'am,

With reference to the captioned subject and pursuant to the provisions of Regulation 30 and Regulation 33 of SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company in its meeting held today, 26th May 2025 has considered and approved the Audited Financial Results along with the Audit Reports of the Company for quarter and financial year ended March 31st, 2025. a Copy of which is enclosed herewith.

We wish to further inform you that the meeting of the board of directors commenced at 05:00 P.M. and concluded at 05:30 P.M.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You.

For and on behalf of
Brawn Biotech Limited



Priyanka Sharma
Company Secretary and Compliance Officer
Membership No.: A50385
Encl: As above



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in
Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

...for better life



Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Brawn Biotech Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of Brawn Biotech Limited (the "Company") for the quarter ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. are presented in accordance with requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2025 and for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Act read with the relevant rules issued thereunder and other accounting principles



generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional Skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to




events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Materiality is the magnitude of misstatements in the statement that, individually or in aggregate makes it probable that the economic decisions of a reasonably knowledgeable user of the statement may be influenced, We consider quantitative materiality and qualitative factors in (i) Planning the scope of our audit, work and in evaluating the results of our work; and (ii) to evaluate the effects of any identified misstatements in the statements
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
- We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 18764N


Rajeev Jain
(Partner)

Membership No.: 099767
UDIN: 25099767BMIVFY5423
Place: Delhi
Date: 26-05-2025





BRAWN BIOTECH LTD.

BRAWN BIOTECH LIMITED						
CIN:L74899DL1985PLC022468						
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024						
STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2025						
Rs. In Lacs						
Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-Mar-25 Un-audited	31-Dec-24 Un-audited	31-Mar-24 Un-audited	31-Mar-25 Audited	31-Mar-24 Audited
1	Revenue from operations					
	Revenue from operations					
	Other Income	225.93	394.48	344.65	1,346.50	1,649.47
	Total Revenue	9.12	0.08	9.39	9.33	8.61
2	Expenses	295.04	384.56	353.04	1,355.83	1,658.27
a	Cost of material consumed					
b	Purchase of stock-in-trade					
		318.00	800.26	489.25	1,638.05	1,558.90
c	Change in inventories of finished goods, work in progress and stock in trade					
d	Employee Benefit expenses	(122.94)	(454.49)	(200.70)	(445.04)	(122.53)
e	Depreciation and amortisation expenses	22.49	20.93	32.11	112.63	140.01
f	Finance Cost	3.13	3.08	2.77	11.46	9.94
g	Other expenses	0.21	0.01	0.22	0.37	0.38
	Total Expenses	69.50	57.95	63.57	218.17	225.99
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	284.49	427.75	387.22	1,535.64	1,812.70
4	Other Income	(49.44)	(43.18)	(34.18)	(179.81)	(154.42)
5	Profit from ordinary activities before exceptional items (3-4)	-	-	-	-	-
6	Exceptional Items	(49.44)	(43.18)	(34.18)	(179.81)	(154.42)
7	Profit from ordinary activities before tax (5-6)	-	-	-	-	-
8	Tax Expenses	(49.44)	(43.18)	(34.18)	(179.81)	(154.42)
9	Profit (Loss) for the period from continuing operations (7-8)	-	-	-	-	-
10	Profit/(loss) from discontinuing operations	(49.44)	(43.18)	(34.18)	(179.81)	(154.42)
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/(loss) from Discontinuing Operations (after tax) (10-11)	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	(49.44)	(43.18)	(34.18)	(179.81)	(154.42)
14	Other Comprehensive Income	(49.44)	(43.18)	(34.18)	(179.81)	(154.42)
	Total Comprehensive Income	(0.06)	0.06	0.70	3.73	0.28
15	Details of equity share capital	(49.52)	(43.12)	(33.48)	(176.08)	(154.14)
	Paid-up equity share capital	300.03	300.03	300.03	300.03	300.03
	Face value of equity share capital					
16	Reserve excluding Revaluation Reserve					
17	Earnings per share					
i	Basic earnings per share					
ii	Diluted earnings per share	(1.85)	(1.44)	(1.12)	(5.87)	(5.14)
		(1.85)	(1.44)	(1.12)	(5.87)	(5.14)

NOTES :-

- Results for the quarter and year ended on 31st March, 2025 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 26th May, 2025.
- The Statutory Auditors carried out the audit for year ended 31st March, 2025. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment) rules, 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 105 dealing with Operating Segments.
- The above Standalone audited Financial Results for the quarter and year ended ended on 31.03.2025 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Figures for the quarter ended 31st March 2025 are the differences between the figures for the year ended 31st March 2025 and Nine month ended 31st December 2024.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited
Brij Raj Gupta
Director
DIN NO. 00574969
Date: 25-05-2025
Place: Delhi



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnlabs.in | Website : www.brawngroup.in
Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

... for better life




BRAWN BIOTECH LTD.

BRAWN BIOTECH LIMITED
CIN:L74899DL1985PLC022468
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024

Statement of Assets and Liabilities as on 31st March 2025			Rs. in Lacs	
Particulars				
	31-Mar-25 Audited	31-Mar-24 Audited		
ASSETS				
(1) Non-Current Assets				
Property, Plant, Equipment & Intangible Assets				
Financial Assets	46.04	33.34		
- Investment				
- Trade Receivable				
- Loan	201.35	65.93		
Deferred Tax Asset (Net)				
	51.46	45.66		
Total Non-Current Assets	298.85	144.92		
(2) Current Assets				
Inventories				
Financial Assets	1,046.70	601.66		
- Trade Receivables				
- Cash and cash equivalents	341.34	388.30		
- Loan	19.95	39.73		
- Other Financial Assets	1.93	2.04		
Current Tax Assets (Net)	119.67	112.65		
Other Current Assets	-	-		
Total Current Assets	220.47	169.57		
TOTAL ASSETS	1,750.05	1,313.95		
	2,048.90	1,458.88		
EQUITY AND LIABILITIES				
EQUITY				
Equity Share Capital				
Other Equity	300.03	300.03		
TOTAL EQUITY	36.20	206.47		
LIABILITIES	336.23	506.50		
(1) Non-current Liabilities				
Financial Liabilities				
- Trade Payable				
- Other Financial Liabilities	771.27	289.88		
Provisions				
Deferred Tax liabilities (Net)	8.74	11.73		
Total Non-Current Liabilities	780.01	301.61		
(2) Current Liabilities				
Financial Liabilities				
- Trade Payables				
- Other Financial Liabilities	823.78	567.49		
Other current liabilities	31.40	38.08		
Provisions	69.91	37.14		
Current tax liabilities	7.58	8.05		
Total Current Liabilities	932.66	650.76		
TOTAL EQUITY AND LIABILITIES	2,048.90	1,458.88		

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Place: New Delhi
Date: 26-05-2025



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA

Email: distribution@brawnlabs.in | Website : www.brawngroup.in

Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331

Email: solution@brawnbiotech.com

... for better life



Brawn Biotech Limited
Cash Flow Statement for the year ended 31st March, 2025
CIN NO: L74899DL1985PLC022468

BRAWN BIOTECH LTD.

Particulars	For the year ended		(Figures In Lakhs)	
	31.03.2025		31.03.2024	
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax				
<i>Adjustments for:</i>		(179.81)		(154.42)
Profit of sale of investment (Shares)				
Depreciation and amortisation	11.46		5.12	
Re-measurement losses on defined benefit plans	3.73		0.26	
Finance costs	0.37	15.55	0.38	5.77
Operating profit / (loss) before working capital changes				
<i>Changes in working capital:</i>		(164.25)		(148.65)
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Inventories				
Trade receivables	(445.04)		(122.53)	
Long Term - Trade receivables	46.97		143.23	
Short-term loans and advances	(135.43)		(5.99)	
Long-term loans and advances	(57.80)		1.12	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables				
Long Term - Trade payables	256.29		(79.41)	
Borrowings	481.40		282.08	
Other current liabilities				
Other financial liabilities	32.77		(70.65)	
Current tax liabilities	(5.59)		(4.36)	
Long-term provisions				
Short-term provisions	(3.00)			
Cash flow from extraordinary items	(0.47)	169.00	2.06806	146.08
Cash generated from operations			0.5223	
Net income tax (paid) / refunds & Dividend		4.74		(2.56)
Net cash flow from / (used in) operating activities (A)		4.74		(2.56)
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advances	(24.16)		(1.21)	
Cash flow from extraordinary items				
Net cash flow from / (used in) Investing activities (B)		(24.16)		(0.01)
C. Cash flow from financing activities				
Proceeds from long-term borrowings				
Proceeds from other short-term borrowings				
Finance cost	(0.37)		(0.38)	
Cash flow from extraordinary items				
Net cash flow from / (used in) financing activities (C)		(0.37)		(0.38)
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		(19.78)		(2.95)
Cash and cash equivalents at the beginning of the year		0.40		43.88
Effect of exchange differences on restatement of foreign currency Cash and cash				
Cash and cash equivalents at the end of the year		(19.39)		40.93
Reconciliation of Cash and cash equivalents with the Balance Sheet:				
Cash and cash equivalents as per Balance Sheet (Refer Note- B)		19.95		39.73
Less: Bank balances not considered as Cash and cash equivalents		19.95		39.73
Net Cash and cash equivalents		19.95		39.73
Add: Current investments considered as part of Cash and cash equivalents		19.95		39.73
Cash and cash equivalents at the end of the year *		19.95		39.73
* Comprises:				
(a) Cash on hand				
(b) Cheques, drafts on hand		3.09		0.45
(c) Balances with banks				
(i) In current accounts				
(ii) Bank deposit Accounts with more than 3 months maturity		15.86		39.28
Notes:		1.00		-

(i) The Cash Flow Statement reflects the combined cash flows pertaining to continuing and discounting operations.
(ii) These earmarked account balances with banks can be utilised only for the specific identified purposes.

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
DIN NO. 00974969
Date: 26-05-2025
Place: Delhi



BRAWN BIOTECH LTD.

CIN NO.: L74899DL1985PLC022468

Works : Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA
Email: distribution@brawnbiotech.com | Website : www.brawngroup.in
Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331
Email: solution@brawnbiotech.com

...for better life